Patents Assigned to AI Therapeutics, Inc.
  • Rapamycin for the treatment of lymphangioleiomyomatosis
    Patent number: 11744797
    Abstract: The present invention relates to methods and compositions for treating lymphangioleiomyomatosis in a human subject in need of such treatment. The methods comprise administering to the subject via inhalation an aerosol composition comprising rapamycin or a prodrug or derivative (including analog) thereof.
    Type: Grant
    Filed: August 27, 2021
    Date of Patent: September 5, 2023
    Assignee: AI Therapeutics, Inc.
    Inventors: Henri Lichenstein, Jonathan M. Rothberg, Thomas Armer, Lawrence S. Melvin, Jr.
  • INHALABLE RAPAMYCIN FORMULATION FOR THE TREATMENT OF PULMONARY HYPERTENSION
    Publication number: 20230255944
    Abstract: The present invention relates to methods and compositions for the treatment and prophylaxis of pulmonary arterial hypertension (PAH) in a human subject in need of such treatment, the methods comprising the pulmonary administration to the subject, preferably via inhalation of a composition comprising rapamycin or a prodrug or derivative thereof.
    Type: Application
    Filed: October 14, 2022
    Publication date: August 17, 2023
    Applicant: AI Therapeutics, Inc.
    Inventors: Thomas Armer, Lawrence S. Melvin, JR., Jonathan M. Rothberg, Henri Lichenstein
  • COMBINATION THERAPY WITH APILIMOD AND GLUTAMATERGIC AGENTS
    Publication number: 20230069069
    Abstract: Provided are compositions and methods related to the use of apilimod in combination with glutamatergic agents for treating neurological diseases and disorders, and for the treatment of cancer.
    Type: Application
    Filed: July 12, 2022
    Publication date: March 2, 2023
    Applicant: AI Therapeutics, Inc.
    Inventors: Henri Lichenstein, Sean Landrette, Peter Ronald Young, Jonathan M. Rothberg
  • Inhalable rapamycin formulation for the treatment of pulmonary hypertension
    Patent number: 11491143
    Abstract: The present invention relates to methods and compositions for the treatment and prophylaxis of pulmonary arterial hypertension (PAH) in a human subject in need of such treatment, the methods comprising the pulmonary administration to the subject, preferably via inhalation of a composition comprising rapamycin or a prodrug or derivative thereof.
    Type: Grant
    Filed: December 27, 2019
    Date of Patent: November 8, 2022
    Assignee: AI Therapeutics, Inc.
    Inventors: Thomas Armer, Lawrence S. Melvin, Jr., Jonathan M. Rothberg, Henri Lichenstein
  • Combination therapy with apilimod and glutamatergic agents
    Patent number: 11439649
    Abstract: Provided are compositions and methods related to the use of apilimod in combination with glutamatergic agents for treating neurological diseases and disorders, and for the treatment of cancer.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: September 13, 2022
    Assignee: AI Therapeutics, Inc.
    Inventors: Henri Lichenstein, Sean Landrette, Peter R. Young, Jonathan M. Rothberg
  • Apilimod compositions and methods for using same
    Patent number: 11266654
    Abstract: The present invention relates to methods for treating cancer with apilimod and related compositions and methods.
    Type: Grant
    Filed: December 27, 2019
    Date of Patent: March 8, 2022
    Assignee: AI Therapeutics, Inc.
    Inventors: Henri Lichenstein, Jonathan M. Rothberg, Sophia Gayle, Neil Beeharry, Paul Beckett, Sean Landrette, Chris Conrad, Matt Dyer, Tian Xu
  • Apilimod compositions and methods for using same in the treatment of renal cancer
    Patent number: 11166944
    Abstract: The present disclosure relates to methods for treating renal cancer with apilimod and related compositions and methods.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: November 9, 2021
    Assignee: AI Therapeutics, Inc.
    Inventors: Neil Beeharry, Sophia Gayle, Sean Landrette, Paul Beckett, Chris Conrad, Tian Xu, Jonathan M. Rothberg, Henri Lichenstein
  • Rapamycin for the treatment of lymphangioleiomyomatosis
    Patent number: 11123289
    Abstract: The present invention relates to methods and compositions for treating lymphangioleiomyomatosis in a human subject in need of such treatment. The methods comprise administering to the subject via inhalation an aerosol composition comprising rapamycin or a prodrug or derivative (including analog) thereof.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: September 21, 2021
    Assignee: AI Therapeutics, Inc.
    Inventors: Henri Lichenstein, Jonathan M. Rothberg, Thomas Armer, Lawrence S. Melvin, Jr.
  • Inhalable rapamycin formulation for treating age-related conditions
    Patent number: 11103449
    Abstract: The present invention relates to methods and compositions for anti-aging therapy and for the treatment and prophylaxis of age-related diseases and disorders in a human subject in need of such therapy or treatment, the methods comprising the pulmonary administration to the subject, preferably via inhalation, of composition comprising rapamycin, or a prodrug or derivative thereof.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: August 31, 2021
    Assignee: AI Therapeutics, Inc.
    Inventors: Thomas Armer, Lawrence S. Melvin, Jr., Jonathan M. Rothberg, Henri Lichenstein
  • Apilimod for use in the treatment of melanoma
    Patent number: 10765682
    Abstract: The present invention relates to methods for treating melanoma with apilimod and related compositions and methods.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: September 8, 2020
    Assignee: AI Therapeutics, Inc.
    Inventors: Neil Beeharry, Sophia Gayle, Sean Landrette, Paul Beckett, Chris Conrad, Tian Xu, Jonathan M. Rothberg, Henri Lichenstein
  • Combination therapy with apilimod and glutamatergic agents
    Patent number: 10751345
    Abstract: Provided are compositions and methods related to the use of apilimod in combination with glutamatergic agents for treating neurological diseases and disorders, and for the treatment of cancer.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: August 25, 2020
    Assignee: AI Therapeutics, Inc.
    Inventors: Henri Lichenstein, Sean Landrette, Peter R. Young, Jonathan M. Rothberg
  • Anti-viral compositions containing PIKfyve inhibitors and use thereof
    Patent number: 10729694
    Abstract: The present invention relates to compositions containing a PIKfyve inhibitor, preferably apilimod, APY0201 or YM-201636, most preferably apilimod, for use in treating or preventing viral infections, preferably Ebola or Marburg virus infections. It also relates to a pharmaceutical pack or kit comprising apillimod and at least one additional anti-viral agent.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: August 4, 2020
    Assignee: AI Therapeutics, Inc.
    Inventors: Henri Lichenstein, Jonathan M. Rothberg, Neil Beeharry, Paul Beckett, Sean Landrette, Chris Conrad
  • Compositions and methods relating to the radioprotective effects of apilimod
    Patent number: 10702534
    Abstract: The present disclosure relates to methods for preventing or treating a radiation-induced disease, disorder, or condition by administering apilimod to a subject in need thereof, and related compositions.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: July 7, 2020
    Assignee: AI Therapeutics, Inc.
    Inventors: Sean Landrette, Tian Xu, Jonathan M. Rothberg, Henri Lichenstein
  • Methods for treating cancer using apilimod
    Patent number: 10350213
    Abstract: The present invention relates to methods for treating cancer with apilimod and related compositions and methods.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: July 16, 2019
    Assignee: AI Therapeutics, Inc.
    Inventors: Henri Lichenstein, Jonathan M. Rothberg, Sophia Gayle, Neil Beeharry, Paul Beckett, Sean Landrette, Chris Conrad, Tian Xu
  • Rapamycin for the treatment of lymphangioleiomyomatosis
    Patent number: 10307371
    Abstract: The present invention relates to methods and compositions for treating lymphangioleiomyomatosis in a human subject in need of such treatment. The methods comprise administering to the subject via inhalation an aerosol composition comprising rapamycin or a prodrug or derivative (including analog) thereof.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: June 4, 2019
    Assignee: AI Therapeutics, Inc.
    Inventors: Thomas Armer, Lawrence S. Melvin, Jr., Jonathan M. Rothberg, Henri Lichenstein
  • Rapamycin for the treatment of lymphangioleiomyomatosis
    Patent number: 10307370
    Abstract: The present invention relates to methods and compositions for treating lymphangioleiomyomatosis in a human subject in need of such treatment. The methods comprise administering to the subject via inhalation an aerosol composition comprising rapamycin or a prodrug or derivative (including analog) thereof.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: June 4, 2019
    Assignee: AI Therapeutics, Inc.
    Inventors: Henri Lichenstein, Jonathan M. Rothberg, Thomas Armer, Lawrence S. Melvin, Jr.